Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.
Authors
- Hana Klamová (ORCID: https://orcid.org/0009-0000-5020-7040)
- Eduard Cmunt (ORCID: https://orcid.org/0000-0001-6486-7402)
- Tereza Jurková (ORCID: https://orcid.org/0000-0002-7383-700X)
- Ivana Ježíšková (ORCID: https://orcid.org/0000-0001-8760-7718)
- Edgar Faber (ORCID: https://orcid.org/0000-0002-3259-7791)
- O Cerná (ORCID: https://orcid.org/0000-0002-0293-788X)
- Jiřı́ Mayer (ORCID: https://orcid.org/0000-0003-0567-9887)
- Kateřina Machová Poláková (ORCID: https://orcid.org/0000-0002-7398-5555)
- Daniela Žáčková (ORCID: https://orcid.org/0000-0001-9802-8148)
- Lukáš Stejskal
- Marika Chrápavá
- Michal Karas (ORCID: https://orcid.org/0000-0001-8824-1594)
- Petra Bělohlávková (ORCID: https://orcid.org/0000-0001-8728-7443)
- Павел Зак (ORCID: https://orcid.org/0000-0003-4465-5343)
Institutions
- Central European Institute of Technology (CZ)
- Charles University (CZ)
- Masaryk University (CZ)
- University Hospital Ostrava (CZ)
- Central European Institute of Technology – Masaryk University (CZ)
- Institute of Haematology and Blood Transfusion (CZ)
- University Hospital Brno (CZ)
- University Hospital Olomouc (CZ)
- University Hospital Plzen (CZ)
- University Hospital Hradec Králové (CZ)
- University Hospital Kralovske Vinohrady (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70158
- Citations
- 3
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36